期刊文献+

体外反搏联合辅酶Q10治疗不稳定型心绞痛患者的疗效

Efficacy of external counterpulsation combined with coenzyme Q10 in patients with unstable angina pectoris
下载PDF
导出
摘要 目的探讨体外反搏(external counterpulsation,ECP)联合辅酶Q10治疗不稳定型心绞痛(unstable angina pectoris,UAP)的效果。方法选取60例UAP患者作为研究对象,用随机数字表法分为观察组与对照组,每组30例。2组均接受常规治疗,在此基础上对照组予以ECP技术治疗,观察组予以ECP联合辅酶Q10治疗。比较2组患者的疗效,治疗前后临床症状、SYNTAX评分的变化,比较单核细胞/高密度脂蛋白胆固醇(monocyte to high-density lipoprotein cholesterol ratio,MHR)水平。结果治疗后,观察组的总有效率高于对照组(P<0.05);观察组患者的SYNTAX评分、心绞痛持续时间及发作次数、MHR值均低于对照组,高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)水平高于对照组(P<0.05)。结论ECP联合辅酶Q10治疗UAP患者,可有效减轻其临床症状,降低MHR值,改善冠状动脉病变,提高治疗效果。 Objective To explore the effect of external counterpulsation(ECP)combined with coenzyme Q10 in patients with unstable angina pectoris(UAP).Methods 60 UAP patients in the hospital were enrolled and divided into observation group and control group according to random number table method,30 cases in each group.The both groups received conventional treatment.On this basis,the observation group was treated with ECP combined with coenzyme Q10.The curative effects of the 2 groups were compared,the clinical symptoms,SYNTAX score changes before and after treatment,and monocyte to high-density lipoprotein cholesterol ratio(MHR)levels were counted.Results The total effective rate of UAP patients in the observation group was higher than that in the control group(P<0.05).After treatment,the SYNTAX score,duration of angina pectoris,number of episodes,monocyte count,and MHR value of UAP patients in the observation group were lower than in the control group,and the high density lipoprotein cholesterol(HDL-C)level was higher than that in the control group(P<0.05).Conclusion ECP combined with coenzyme Q10 in the treatment of UAP patients can effectively reduce clinical symptoms,reduce MHR values,improve coronary artery disease,and improve treatment effects.
作者 杨然 高丽华 孙玉艳 YANG Ran;GAO Lihua;SUN Yuyan(Department of Pharmacy,Kailuan General Hospital,Tangshan 063000,China;Department of Cardiology,Cangzhou People’s Hospital,Cangzhou 061000,China;Department of Cardiology,Kailuan General Hospital,Tangshan 063000,China)
出处 《西北药学杂志》 CAS 2024年第4期112-115,共4页 Northwest Pharmaceutical Journal
基金 河北省2021年度医学科学研究课题计划(编号:20210745)。
关键词 辅酶Q10 体外反搏(ECP) 不稳定型心绞痛(UAP) 单核细胞/高密度脂蛋白胆固醇(MHR) SYNTAX评分 coenzyme Q10 external counterpulsation(ECP) unstable angina pectoris(UAP) monocyte to high-density lipoprotein cholesterol ratio(MHR) SYNTAX score
  • 相关文献

参考文献8

二级参考文献98

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:193
  • 2沈杰,沈卫峰.替罗非班在急性冠脉综合征介入治疗中的应用[J].国际心血管病杂志,2006,33(3):156-159. 被引量:72
  • 3耿现仓.硝苯地平缓释片治疗慢性稳定型心绞痛疗效观察[J].中国乡村医药,2007,14(5):11-12. 被引量:1
  • 4Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 5Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 6Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 7CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 8Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 9Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 10Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.

共引文献2700

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部